重组组织型纤溶酶原激活剂溶栓治疗急性心肌梗死临床观察  

The clinical study of recombinant tissue-type plasmiogen activator in thrombolytic therapy of acute myocardial infarction

作　　者：蒋宝琦[1] 朱继红[1] 刘健[1] 吴淳[1] 

机构地区：[1]北京医科大学人民医院心内科

出　　处：《北京医科大学学报》1999年第2期152-154,共3页Journal of Peking University(Health Sciences)

摘　　要：观察重组组织和纤溶酶原激活剂治疗急性心肌梗死的疗效。方法：５３例急性心肌梗死患者于６０ｍｉｎ或９０内给予ｒｔ－ＰＡ总量为５０ｍｇ，观察血管再通的临床指标，低血压，出血及寒战等并发症。结果：总血管再通４２例，其中，６０ｍｉｎ组及９０ｍｉｎ组再通者分别有１９例。To evaluate efficacy and safety of intravenous recombinant tissue-type plasminogen activator (rt-PA) in treatment of acute myocardial infarction (AMI). Methods: Fifty- three patients with AMI admitted to our hospital from April 1995 to December 1997 were confirmed to the inclusion and exclusion criteria of thrombolytic therapy. The patients were divided into two groups, twenty-eight patients in group A and twenty-five patients in group B, and to receive rt-PA intravenous (i. v. ) blous 10 mg in 5 min, follbwed by a 40 mg i. v, infusion over 55 min, or over 85 min. The clinical criteria of reperfusion were evaluated. Results: The reperfusion rate of group A was 67. 9 % (19/28) and group B 92. 0 % (23/25 ). The total reperfusion rate was 79. 3 % (42/53 ) in 53 patients treated with rt-PA. Hypotension, mild bleeding, rigor occurred, respectively, in 11. 3% (6/ 53), 13. 2% (7/53) and 1. 87% (1/53) of patients with rt-PA. Conclusion: rt-PA is a safe and effective thrombolytic agent.

关 键 词：心肌梗死 药物疗法 AMI RT-PA 

分 类 号：R542.220.5[医药卫生—心血管疾病] R972[医药卫生—内科学]